Patrys (ASX: PAB) has initiated key manufacturing and regulatory activities for its RLS-2201 program, targeting an expedited 505(b)(2) pathway for delirium treatment with the US Food & Drug Administration (FDA).
Engineering batch manufacturing of RLS-2201 has commenced with BioCina, a crucial step designed to replicate commercial-scale processes.
The manufacturing process will support stability testing and generate early clinical material.
It also sets the stage for future Good Manufacturing Practice (GMP) material production, essential for Phase I dosing and process validation.
FDA Pathway Engagement
US regulatory engagement has begun with Facet Life Sciences. This collaboration is aimed at preparing for an FDA Investigational New Drug (IND) submission for RLS-2201.
The regulatory strategy focuses on the FDA 505(b)(2) pathway. This route leverages existing safety data from oral Quetiapine, potentially accelerating the development timeline.
Phase 0 first-in-human trials are planned for H2 2026. The company expects to finalise the selection of a Contract Research Organisation (CRO) in Q2 2026.
Delirium Program Advancement
The initiation of manufacturing and regulatory steps signifies a de-risking of the RLS-2201 program.
This advancement adds a value-creating program to Patrys' pipeline, presenting potential near-term catalysts.
Previous investor presentations in January 2026 highlighted the significant market opportunity for delirium treatment, estimated at approximately $2 billion annually.
The company's injectable reformulation (AQS, now RLS-2201) of quetiapine targets this large, unmet medical need across intensive care, palliative care, and aged care settings.
Leadership Context
Dr Samantha South was appointed Chief Executive Officer in February 2026.
She brings extensive experience in translational science and regulatory strategy.
Dr South's appointment is expected to accelerate clinical progression and value creation across Patrys' expanded pipeline.
Her expertise aligns with the company's evolution into a dual-platform, catalyst-driven, clinical-stage entity.
Outlook and Risks
Patrys is strategically advancing its RLS-2201 program by commencing manufacturing and engaging with regulatory bodies under an expedited FDA 505(b)(2) pathway.
While these steps de-risk the program and target a significant market, execution and regulatory success remain contingent on agency feedback and timely completion of manufacturing and CRO timelines.
Investors should note that funding for later-stage trials and commercialisation remains a key consideration, along with potential delays in regulatory approval.
